LENZ
LENZ Therapeutics, Inc.
$5.59
-0.20
(-3.45%)
Mkt Cap
175.27M
Volume
1,202,745
52W Range
5.23-50.4
Sector
Healthcare
Beta
1.62
EPS (TTM)
-3.60
P/E Ratio
-5.61
Revenue (TTM)
20.99M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 19.09M | 0 | 0 | 15.00M | 0 | 0 | 0 |
| Net Income | (82.13M) | (49.77M) | (69.97M) | (10.81M) | (70.76M) | (68.37M) | (109,000) |
| EPS | -2.85 | -2.34 | -15.30 | -12.89 | -8.54 | -8.24 | -0.01 |
| Free Cash Flow | (70.00M) | (59.86M) | (60.41M) | (94.57M) | (58.59M) | (10.27M) | (19,000) |
| FCF / Share | -2.43 | -2.81 | -7.42 | -12.06 | -7.07 | -1.24 | -0.00 |
| Operating CF | (69.17M) | (59.39M) | (60.38M) | (87.98M) | (52.85M) | (8.72M) | (19,000) |
| Total Assets | 305.88M | 215.30M | 70.38M | 46.95M | 18.34M | 22.56M | 6,000 |
| Total Debt | 815,000 | 1.38M | 329,000 | 250,000 | 0 | 0 | 2.21M |
| Cash & Equiv | 25.18M | 20.16M | 35.14M | 44.44M | 18.31M | 19.82M | 6,000 |
| Book Value | 284.34M | 204.08M | (92.71M) | (24.17M) | (14.21M) | (9.80M) | (2.22M) |
| Return on Equity | -0.29 | -0.24 | N/A | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.90M | 1.59M | 12.50M | 5.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (41.49M) | (35.90M) | (16.70M) | (14.91M) | (14.62M) | (12.65M) | (10.21M) | (10.25M) | (16.65M) | (23.69M) | (18.88M) | (14.73M) |
| EPS | -1.32 | -1.16 | -0.59 | -0.53 | -0.53 | -0.46 | -0.38 | -0.40 | -3.53 | -2.77 | -2.75 | -6.82 |
| Free Cash Flow | (33.60M) | (33.06M) | (9.03M) | (11.75M) | (16.16M) | (9.23M) | (10.77M) | (15.93M) | (23.94M) | (20.97M) | (13.09M) | (4.89M) |
| FCF / Share | -1.07 | -1.06 | -0.32 | -0.42 | -0.59 | -0.34 | -0.40 | -0.62 | -5.07 | -2.53 | -1.60 | -0.60 |
| Operating CF | (33.58M) | (33.02M) | (8.59M) | (11.51M) | (16.05M) | (9.08M) | (10.58M) | (15.79M) | (23.94M) | (20.97M) | (13.09M) | (5.25M) |
| Total Assets | 272.54M | 305.88M | 210.70M | 217.33M | 201.25M | 215.30M | 224.01M | 202.64M | 217.32M | 70.38M | 92.17M | 287.04M |
| Total Debt | 673,000 | 815,000 | 954,000 | 1.05M | 1.18M | 1.38M | 1.58M | 1.70M | 589,000 | 329,000 | 360,000 | 53.54M |
| Cash & Equiv | 24.77M | 25.18M | 25.40M | 37.61M | 23.04M | 20.16M | 41.05M | 84.03M | 200.36M | 35.14M | 42.85M | 128.51M |
| Book Value | 246.49M | 284.34M | 193.93M | 206.37M | 192.01M | 204.08M | 215.28M | 192.92M | 198.17M | (92.71M) | (69.57M) | 224.15M |
| Return on Equity | -0.17 | -0.13 | -0.09 | -0.07 | -0.08 | -0.06 | -0.05 | -0.05 | -0.08 | N/A | N/A | -0.07 |
LENZ News
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
LENZ Therapeutics to Participate in Upcoming Investor Conferences
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
LENZ Therapeutics Q1 Earnings Call Highlights
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights